Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SAD448 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| SAD448 | DRUG | - |
Key inclusion criteria: * Males and females, 18 - 65 years of age, with ocular hypertension * Females must be post-menopausal or surgically sterile Key exclusion criteria: * Diagnosis of glaucoma in either eye * A history of or current eye conditions or medical problems that would prohibit the us...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| SpyGlass Pharma, Inc. | SGP | 5 | PHASE3 | Bimatoprost System, BIM-DRS |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Bimatoprost ophthalmic solution |
| AbbVie, Inc. | ABBV | 1 | PHASE1 | AGN-193408 |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE1 | REGN22530 |
| Glaukos Corp | GKOS | 2 | - | Travoprost |
SAD448 is an investigational small molecule developed by Novartis AG for ocular hypertension, a condition of elevated pressure inside the eye. It was studied as a Phase 1 candidate in a single completed clinical trial. SAD448 has not been approved by the FDA and remains in clinical development.
SAD448 was developed for the treatment of ocular hypertension, a condition in which pressure within the eye is elevated. Its only recorded clinical study enrolled adults with ocular hypertension. The drug is investigational and has not been approved for any use.
SAD448 targets the cannabinoid receptors CNR1 and CNR2. It acts as an agonist at these receptors, meaning it activates them. Both receptors are part of the endocannabinoid system. This target profile was the basis for its development as a small molecule for ocular hypertension.
SAD448 is developed by Novartis AG, the Swiss pharmaceutical company whose shares trade under the ticker NVS. Novartis sponsored the Phase 1 study of SAD448 in ocular hypertension. No other developer or partner is associated with the asset.
SAD448 is in Phase 1 development. Its only recorded clinical trial, NCT00503360, was a Phase 1 study that has been completed. The drug is investigational and has not received FDA approval. No active trials of SAD448 are currently listed.
SAD448 has been studied in one clinical trial, NCT00503360, titled Tolerability, Safety and Efficacy of SAD448 in Subjects With Ocular Hypertension. The Phase 1 trial was randomized, double blind, and enrolled 80 participants in Australia. It is completed, and no active trials are listed.